Adicet Bio to Present at Upcoming Investor Conferences
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will participate in three upcoming investor conferences in August.
Details of the events are as follows:
BTIG Biotech Conference, August 8-9, 2022
- Chen Schor, President & CEO, will participate in a fireside chat at the conference on Monday, August 8, 2022.
Wedbush Pacgrow Healthcare Conference, August 9-10, 2022
- Chen Schor, President & CEO, will participate in a virtual panel discussion titled, “A View to a Kill(er) Cell – Part 1” on Wednesday, August 10, 2022, at 1:10 P.M. ET.
Canaccord Genuity Annual Growth Conference, August 8-11, 2022, Boston, Massachusetts
- Chen Schor, President & CEO, will present a corporate overview on Thursday, August 11, 2022, at 11:00 A.M. ET.
The live audio webcast of the Canaccord Genuity presentation and Wedbush panel can be accessed on the Investors section of Adicet Bio’s website at https://investor.adicetbio.com. An archived replay will be available for 30 days following the presentation.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with CAR and T cell receptor-like targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.
Adicet Bio., Inc.
Investor and Media Contacts
Stern Investor Relations, Inc.